Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.82
NAS:IRWD's Cash-to-Debt is ranked lower than
65% of the 719 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. NAS:IRWD: 0.82 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:IRWD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.82  Med: 36.68 Max: 420.39
Current: 0.82
0.82
420.39
Equity-to-Asset 0.09
NAS:IRWD's Equity-to-Asset is ranked lower than
95% of the 660 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. NAS:IRWD: 0.09 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:IRWD' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.86  Med: 0.15 Max: 0.63
Current: 0.09
-1.86
0.63
Piotroski F-Score: 4
Altman Z-Score: 0.77
Beneish M-Score: -2.20
WACC vs ROIC
12.23%
-57.00%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -18.93
NAS:IRWD's Operating Margin % is ranked lower than
81% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.86 vs. NAS:IRWD: -18.93 )
Ranked among companies with meaningful Operating Margin % only.
NAS:IRWD' s Operating Margin % Range Over the Past 10 Years
Min: -1101.36  Med: -157.88 Max: -18.93
Current: -18.93
-1101.36
-18.93
Net Margin % -29.83
NAS:IRWD's Net Margin % is ranked lower than
83% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. NAS:IRWD: -29.83 )
Ranked among companies with meaningful Net Margin % only.
NAS:IRWD' s Net Margin % Range Over the Past 10 Years
Min: -1192.31  Med: -164.11 Max: -29.83
Current: -29.83
-1192.31
-29.83
ROE % -103.79
NAS:IRWD's ROE % is ranked lower than
92% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.66 vs. NAS:IRWD: -103.79 )
Ranked among companies with meaningful ROE % only.
NAS:IRWD' s ROE % Range Over the Past 10 Years
Min: -299.34  Med: -128.16 Max: -48.14
Current: -103.79
-299.34
-48.14
ROA % -12.14
NAS:IRWD's ROA % is ranked lower than
79% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.48 vs. NAS:IRWD: -12.14 )
Ranked among companies with meaningful ROA % only.
NAS:IRWD' s ROA % Range Over the Past 10 Years
Min: -107.22  Med: -35.95 Max: -12.14
Current: -12.14
-107.22
-12.14
ROC (Joel Greenblatt) % -162.35
NAS:IRWD's ROC (Joel Greenblatt) % is ranked lower than
84% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.44 vs. NAS:IRWD: -162.35 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:IRWD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1275.86  Med: -306.95 Max: -159
Current: -162.35
-1275.86
-159
3-Year Revenue Growth Rate 112.10
NAS:IRWD's 3-Year Revenue Growth Rate is ranked higher than
99% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. NAS:IRWD: 112.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:IRWD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -9.3 Max: 112.1
Current: 112.1
0
112.1
3-Year EBITDA Growth Rate -52.90
NAS:IRWD's 3-Year EBITDA Growth Rate is ranked lower than
98% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.70 vs. NAS:IRWD: -52.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:IRWD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -7.6 Max: 51.9
Current: -52.9
0
51.9
3-Year EPS without NRI Growth Rate -38.00
NAS:IRWD's 3-Year EPS without NRI Growth Rate is ranked lower than
90% of the 541 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. NAS:IRWD: -38.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:IRWD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -38 Max: 54.1
Current: -38
0
54.1
GuruFocus has detected 6 Warning Signs with Ironwood Pharmaceuticals Inc $NAS:IRWD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:IRWD's 10-Y Financials

Financials (Next Earnings Date: 2017-05-21 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

IRWD Guru Trades in Q1 2016

Ken Fisher 235,675 sh (New)
Vanguard Health Care Fund 4,522,387 sh (+3.55%)
Eaton Vance Worldwide Health Sciences Fund 1,237,800 sh (unchged)
Jim Simons Sold Out
Steven Cohen 1,180,500 sh (-23.24%)
Paul Tudor Jones 14,044 sh (-47.03%)
» More
Q2 2016

IRWD Guru Trades in Q2 2016

Joel Greenblatt 133,821 sh (New)
Paul Tudor Jones 34,118 sh (+142.94%)
Ken Fisher 242,450 sh (+2.87%)
Vanguard Health Care Fund 4,522,387 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund Sold Out
Steven Cohen 1,167,183 sh (-1.13%)
» More
Q3 2016

IRWD Guru Trades in Q3 2016

Joel Greenblatt 147,976 sh (+10.58%)
Vanguard Health Care Fund 4,522,387 sh (unchged)
Ken Fisher 242,450 sh (unchged)
Paul Tudor Jones 30,489 sh (-10.64%)
Steven Cohen 953,927 sh (-18.27%)
» More
Q4 2016

IRWD Guru Trades in Q4 2016

Vanguard Health Care Fund 4,533,887 sh (+0.25%)
Paul Tudor Jones 28,674 sh (-5.95%)
Joel Greenblatt 131,163 sh (-11.36%)
Ken Fisher 202,850 sh (-16.33%)
Steven Cohen 291,532 sh (-69.44%)
» More
» Details

Insider Trades

Latest Guru Trades with IRWD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:HZNP, NAS:AKRX, NAS:ENDP, OTCPK:IZQVF, NAS:PCRX, NAS:MDCO, NAS:RDUS, NYSE:CTLT, OTCPK:STDAF, NAS:SUPN, NYSE:VRX, OTCPK:KSPHF, NAS:NBIX, NAS:EGRX, NYSE:PTHN, OTCPK:EVTCY, OTCPK:KHTRF, OTCPK:GNMLF, NAS:SGYP, NYSE:DPLO » details
Traded in other countries:I76.Germany,
Ironwood Pharmaceuticals Inc is an entrepreneurial pharmaceutical company. It discovers, develops and commercializes differentiated medicines that improve patient's lives.

Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical firm that discovers, develops, and commercializes innovative medicines targeting important therapeutic needs. The firm has two business segments: human therapeutics and biomanufacturing. Ironwood is focused on a portfolio of internally discovered drug candidates that currently includes one Phase 3 drug candidate (linaclotide), one Phase 1 pain drug candidate, and multiple preclinical candidates.

Ratios

vs
industry
vs
history
PB Ratio 37.63
IRWD's PB Ratio is ranked lower than
98% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.93 vs. IRWD: 37.63 )
Ranked among companies with meaningful PB Ratio only.
IRWD' s PB Ratio Range Over the Past 10 Years
Min: 5.45  Med: 12.25 Max: 47.65
Current: 37.63
5.45
47.65
PS Ratio 9.06
IRWD's PS Ratio is ranked lower than
81% of the 727 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.85 vs. IRWD: 9.06 )
Ranked among companies with meaningful PS Ratio only.
IRWD' s PS Ratio Range Over the Past 10 Years
Min: 3.48  Med: 18.1 Max: 75.43
Current: 9.06
3.48
75.43
Current Ratio 4.17
IRWD's Current Ratio is ranked higher than
74% of the 614 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. IRWD: 4.17 )
Ranked among companies with meaningful Current Ratio only.
IRWD' s Current Ratio Range Over the Past 10 Years
Min: 2.33  Med: 4 Max: 6.54
Current: 4.17
2.33
6.54
Quick Ratio 4.16
IRWD's Quick Ratio is ranked higher than
78% of the 613 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.73 vs. IRWD: 4.16 )
Ranked among companies with meaningful Quick Ratio only.
IRWD' s Quick Ratio Range Over the Past 10 Years
Min: 2.33  Med: 4 Max: 6.54
Current: 4.16
2.33
6.54
Days Inventory 35.20
IRWD's Days Inventory is ranked higher than
89% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.23 vs. IRWD: 35.20 )
Ranked among companies with meaningful Days Inventory only.
IRWD' s Days Inventory Range Over the Past 10 Years
Min: 35.2  Med: 193.31 Max: 1266.91
Current: 35.2
35.2
1266.91
Days Sales Outstanding 1.24
IRWD's Days Sales Outstanding is ranked higher than
98% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.23 vs. IRWD: 1.24 )
Ranked among companies with meaningful Days Sales Outstanding only.
IRWD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.05  Med: 7.61 Max: 889.76
Current: 1.24
0.05
889.76
Days Payable 2.00
IRWD's Days Payable is ranked lower than
97% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.13 vs. IRWD: 2.00 )
Ranked among companies with meaningful Days Payable only.
IRWD' s Days Payable Range Over the Past 10 Years
Min: 2  Med: 513.78 Max: 8217.61
Current: 2
2
8217.61

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.50
IRWD's 3-Year Average Share Buyback Ratio is ranked lower than
59% of the 441 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.00 vs. IRWD: -6.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IRWD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -144.5  Med: -9.9 Max: 0
Current: -6.5
-144.5
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.50
IRWD's Price-to-Median-PS-Value is ranked higher than
90% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. IRWD: 0.50 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IRWD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.45  Med: 1 Max: 3.23
Current: 0.5
0.45
3.23
Earnings Yield (Greenblatt) % -1.66
IRWD's Earnings Yield (Greenblatt) % is ranked lower than
69% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. IRWD: -1.66 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IRWD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1.68  Med: 0 Max: 46.78
Current: -1.66
-1.68
46.78

More Statistics

Revenue (TTM) (Mil) $274.0
EPS (TTM) $ -0.56
Beta1.32
Short Percentage of Float20.22%
52-Week Range $9.06 - 18.53
Shares Outstanding (Mil)147.85

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 326 467 606
EPS ($) -0.69 0.11 0.96
EPS without NRI ($) -0.69 0.11 0.96
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:IRWD

Headlines

Articles On GuruFocus.com
Ken Fisher's Best Investments: Credicorp, Ambev, Tata Motors Jul 11 2016 
A Look at Steven Cohen's Investment in Ironwood Pharmaceuticals Aug 25 2015 
Weekly 3-Year Low Highlight: EXC, RVBD, IRWD, SHOS Oct 27 2013 
Five-Year Lows: Singapore Airlines Limited, Gold Field Ltd., Ironwood Pharmaceuticals Inc., Northwes Oct 22 2013 
Weekly CEO Buys Highlight: GDOT, VOCS, PES, IRWD, ABR Nov 11 2012 
Edward Owens Made Few Purchases In Times of Changes: Boston Scientific Corp., Ironwood Pharmaceutica May 10 2010 
Vanguard Health Care Fund Buys Ironwood Pharmaceuticals Inc., Johnson & Johnson, Boston Scientific C May 06 2010 

More From Other Websites
Ironwood Pharmaceuticals, Inc. :IRWD-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017 Mar 17 2017
Ironwood Pharmaceuticals, Inc. :IRWD-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Mar 14 2017
Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference Mar 10 2017
Ironwood Pharmaceuticals Showcases Progress Delivering Innovative Medicines to Patients and Building... Mar 09 2017
[$$] Celebrating Failure in a Tough Drug Industry Mar 03 2017
Ironwood Pharmaceuticals to Present at Cowen and Company 37th Annual Health Care Conference Feb 28 2017
IRONWOOD PHARMACEUTICALS INC Financials Feb 28 2017
Ironwood Pharmaceuticals to Host R&D Day on March 9, 2017 Feb 23 2017
IRONWOOD PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Feb 22 2017
Ironwood (IRWD) Q4 Loss Narrower than Expected; Sales Top Feb 22 2017
Ironwood reports 4Q loss Feb 21 2017
Ironwood reports 4Q loss Feb 21 2017
IRONWOOD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 21 2017
Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2016 Investor Update Feb 21 2017
Q4 2016 Ironwood Pharmaceuticals Inc Earnings Release - After Market Close Feb 21 2017
Drug Stocks Q4 Earnings Lineup for Feb 21: IRWD, MNTA, EXAS Feb 20 2017
Radius Health (RDUS) Q4 Earnings: Will the Stock Disappoint? Feb 17 2017
5 Drug Stocks Poised to Beat Earnings Estimates in Q4 Feb 09 2017
Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2016 Investor Update Call Feb 07 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)